[1]
|
Kelley, J.R. and Duggan, J.M. (2003) Gastric Cancer Epidemiology and Risk Factors. Journal of Clinical Epidemiology, 56, 1-9. https://doi.org/10.1016/S0895-4356(02)00534-6
|
[2]
|
Health and Welfare Statistics Association (1999) The Movement of Population. J Health Welfare Stat, 46, 41-72.
|
[3]
|
Moon, Y.W., Rha, S.Y., Jeung, H.C., Kim, C., Hong, M.H., Chang, H., Roh, J.K., Noh, S.H., Kim, B.S. and Chung, H.C. (2010) Outcomes of Multiple Salvage Chemotherapy for Advanced Gastric Cancer: Implications for Clinical Practice and Trial Design. Cancer Chemotherapy and Pharmacology, 66, 797-805. https://doi.org/10.1007/s00280-010-1295-z
|
[4]
|
Farhat, F.S., Kattan, J., Chahine, G.Y., Younes, F.C., Nasr, F.L., Mroue, R.M. and Ghosn, M.G. (2010) Role of Low Dose Capecitabine Combined to Irinotecan in Advanced and Metastatic Gastric Cancer. Medical Oncology, 27, 722-727. https://doi.org/10.1007/s12032-009-9275-z
|
[5]
|
Benson, A.B. (2008) Advanced Gastric Cancer: An Update and Future Directions. Gastrointestinal Cancer: Research & Therapy, 2, S47-S53.
|
[6]
|
Kim, Y.H. (2005) Chemotherapy for Advanced Gastric Cancer: Slow but Further Progress. Cancer Research and Treatment, 37, 79-86. https://doi.org/10.4143/crt.2005.37.2.79
|
[7]
|
Wagner, A.D., Grothe, W., Haerting, J., Kleber, G., Grothey, A. and Fleig, W.E. (2006) Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data. Journal of Clinical Oncology, 24, 2903-2909. https://doi.org/10.1200/JCO.2005.05.0245
|
[8]
|
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., Toh, Y., Nagaie, T., Takagi, S., Yamamura, Y., Yanaoka, K., Orita, H. and Takeuchi, M. (2008) S-1 Plus Cisplatin versus S-1 Alone for First-Line Treatment of Advanced Gastric Cancer (SPIRITS Trial): A Phase III Trial. The Lancet Oncology, 9, 215-221. https://doi.org/10.1016/S1470-2045(08)70035-4
|
[9]
|
Yamada, Y., Higuchi, K., Nishikawa, K., Gotoh, M., Fuse, N., Sugimoto, N., Nishina, T., Amagai, K., Chin, K., Niwa, Y., Tsuji, A., Imamura, H., Tsuda, M., Yasui, H., Fujii, H., Yamaguchi, K., Yasui, H., Hironaka, S., Shimada, K., Miwa, H., Hamada, C. and Hyodo, I. (2015) Phase III Study Comparing Oxaliplatin Plus S-1 with Cisplatin plus S-1 in Chemotherapy-Naïve Patients with Advanced Gastric Cancer. Annals of Oncology, 26, 141-148. https://doi.org/10.1093/annonc/mdu472
|
[10]
|
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton G, Daniel, F., Oates, J. and Norman, A.R. (2008) Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. The New England Journal of Medicine, 358, 36-46. https://doi.org/10.1056/NEJMoa073149
|
[11]
|
Kim, Y.S, Sym, S.J., Park, S.H., Park, I., Hong, J., Ahn, H.K., Park, J., Cho, E.K., Lee, W.K., Chung, M., Lee, J.H. and Shin, D.B. (2014) A Randomized Phase II Study of Weekly Docetaxel/Cisplatin versus Weekly Docetaxel/Oxaliplatin as First-Line Therapy for Patients with Advanced Gastric Cancer. Cancer Chemotherapy and Pharmacology, 73, 163-169. https://doi.org/10.1007/s00280-013-2334-3
|
[12]
|
Al-Batran, S.E., Hartmann, J.T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., Rethwisch, V., Seipelt G, Homann, N., Wilhelm, G., Schuch, G., Stoehlmacher, J., Derigs, H.G., Hegewisch-Becker, S., Grossmann, J., Pauligk, C., Atmaca, A., Bokemeyer, C., Knuth, A. and Jäger, E. (2008) Arbeitsgemeinschaft Internistische Onkologie. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology, 26, 1435-1442. https://doi.org/10.1200/JCO.2007.13.9378
|
[13]
|
De Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., Papamichael, D., Le Bail, N., Louvet, C., Hendler, D., De Braud, F., Wilson, C., Morvan, F. and Bonetti, A. (2000) Leucovorin and Fluorouracil with or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology, 18, 2938-2947. https://doi.org/10.1200/JCO.2000.18.16.2938
|
[14]
|
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., Tabah-Fisch, I., De Gramont, A. and for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. (2004) Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. The New England Journal of Medicine, 350, 2343-2451. https://doi.org/10.1056/NEJMoa032709
|
[15]
|
Park, S.B., Goldstein, D., Krishnan, A.V., Lin, C.S., Friedlander, M.L., Cassidy, J., Koltzenburg, M. and Kiernan, M.C. (2013) Chemotherapy-Induced Peripheral Neurotoxicity: A Critical Analysis. CA: A Cancer Journal for Clinicians, 63, 419-437. https://doi.org/10.3322/caac.21204
|
[16]
|
Yamada, Y., Shirao, K., Ohtsu, A., Boku, N., Hyodo, I., Saitoh, H., Miyata, Y. and Taguchi, T. (2001) Phase II Trial of Paclitaxel by Three-Hour Infusion for Advanced Gastric Cancer with Short Premedication for Prophylaxis against Paclitaxel-Associated Hypersensitivity Reactions. Annals of Oncology, 12, 1133-1137.
|
[17]
|
Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., Esaki, T., Nagase, M., Fujitani, K., Yamaguchi, K., Ura, T., Hamamoto, Y., Morita, S., Okamoto, I., Boku, N. and Hyodo, I. (2013) Randomized, Open-Label, Phase III Study Comparing Irinotecan with Paclitaxel in Patients with Advanced Gastric Cancer Without Severe Peritoneal Metastasis after Failure of Prior Combination Chemotherapy Using Fluoropyrimidine plus Platinum: WJOG 4007 Trial. Journal of Clinical Oncology, 31, 4438-4444. https://doi.org/10.1200/JCO.2012.48.5805
|
[18]
|
Miltenburg, N.C. and Boogerd, W. (2014) Chemotherapy-Induced Neuropathy: A Comprehensive Survey. Cancer Treatment Reviews, 40, 872-882. https://doi.org/10.1016/j.ctrv.2014.04.004
|
[19]
|
Argyriou, A.A., Kyritsis, A.P., Makatsoris, T. and Kalofonos, H.P. (2014) Chemotherapy-Induced Peripheral Neuropathy in Adults: A Comprehensive Update of the Literature. Cancer Management and Research, 6, 135-147. https://doi.org/10.2147/CMAR.S44261
|
[20]
|
Eckhoff, L., Knoop, A.S., Jensen, M.B., Ejlertsen, B. and Ewertz, M. (2013) Risk of Docetaxel-Induced Peripheral Neuropathy among 1,725 Danish Patients with Early Stage Breast Cancer. Breast Cancer Research and Treatment, 142, 109-118. https://doi.org/10.1007/s10549-013-2728-2
|
[21]
|
Schneider, B.P., Zhao, F., Wang, M., Stearns, V., Martino, S., Jones, V., Perez, E.A., Saphner, T., Wolff, A.C., Sledge Jr., G.W., Wood, W.C., Davidson, N.E. and Sparano, J.A. (2012) Neuropathy Is Not Associated with Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer. Journal of Clinical Oncology, 30, 3051-3057. https://doi.org/10.1200/JCO.2011.39.8446
|
[22]
|
Koizumi, W., Takiuchi, H., Yamada, Y., Boku, N., Fuse, N., Muro, K., Komatsu, Y. and Tsuburaya, A. (2010) Phase II Study of Oxaliplatin Plus S-1 as First-Line Treatment for Advanced Gastric Cancer (G-SOX Study). Annals of Oncology, 21, 1001-1005. https://doi.org/10.1093/annonc/mdp464
|
[23]
|
Hironaka, S., Zenda, S., Boku, N., Fukutomi, A., Yoshino, T. and Onozawa, Y. (2006) Weekly Paclitaxel as Second-Line Chemotherapy for Advanced or Recurrent Gastric Cancer. Gastric Cancer, 9, 14-18. https://doi.org/10.1007/s10120-005-0351-6
|